JP2020529847A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020529847A5 JP2020529847A5 JP2020505464A JP2020505464A JP2020529847A5 JP 2020529847 A5 JP2020529847 A5 JP 2020529847A5 JP 2020505464 A JP2020505464 A JP 2020505464A JP 2020505464 A JP2020505464 A JP 2020505464A JP 2020529847 A5 JP2020529847 A5 JP 2020529847A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- immune cells
- types
- cells
- lymphocytes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 59
- 210000002865 immune cell Anatomy 0.000 claims description 48
- 201000011510 cancer Diseases 0.000 claims description 37
- 238000000034 method Methods 0.000 claims description 35
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 33
- 230000004927 fusion Effects 0.000 claims description 29
- 210000004698 lymphocyte Anatomy 0.000 claims description 28
- 239000003814 drug Substances 0.000 claims description 24
- 210000004990 primary immune cell Anatomy 0.000 claims description 15
- 229920001184 polypeptide Polymers 0.000 claims description 13
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 13
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 12
- 239000000427 antigen Substances 0.000 claims description 11
- 102000036639 antigens Human genes 0.000 claims description 11
- 108091007433 antigens Proteins 0.000 claims description 11
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims description 8
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims description 8
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims description 8
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 8
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 8
- 206010038389 Renal cancer Diseases 0.000 claims description 8
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 8
- 206010017758 gastric cancer Diseases 0.000 claims description 8
- 238000000338 in vitro Methods 0.000 claims description 8
- 201000010982 kidney cancer Diseases 0.000 claims description 8
- 201000007270 liver cancer Diseases 0.000 claims description 8
- 208000014018 liver neoplasm Diseases 0.000 claims description 8
- 206010038038 rectal cancer Diseases 0.000 claims description 8
- 201000001275 rectum cancer Diseases 0.000 claims description 8
- 201000011549 stomach cancer Diseases 0.000 claims description 8
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 claims description 8
- 210000000822 natural killer cell Anatomy 0.000 claims description 7
- 208000009956 adenocarcinoma Diseases 0.000 claims description 6
- 230000000259 anti-tumor effect Effects 0.000 claims description 6
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 208000005440 Basal Cell Neoplasms Diseases 0.000 claims description 4
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 4
- 206010061692 Benign muscle neoplasm Diseases 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 201000009030 Carcinoma Diseases 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 206010014733 Endometrial cancer Diseases 0.000 claims description 4
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 4
- 206010018338 Glioma Diseases 0.000 claims description 4
- 208000017604 Hodgkin disease Diseases 0.000 claims description 4
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 4
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 4
- 206010023825 Laryngeal cancer Diseases 0.000 claims description 4
- 208000003445 Mouth Neoplasms Diseases 0.000 claims description 4
- 201000004458 Myoma Diseases 0.000 claims description 4
- 206010029260 Neuroblastoma Diseases 0.000 claims description 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 201000000582 Retinoblastoma Diseases 0.000 claims description 4
- 206010039491 Sarcoma Diseases 0.000 claims description 4
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 4
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 4
- 206010057644 Testis cancer Diseases 0.000 claims description 4
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 4
- 201000009036 biliary tract cancer Diseases 0.000 claims description 4
- 208000020790 biliary tract neoplasm Diseases 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 4
- 201000007455 central nervous system cancer Diseases 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- 210000004252 chorionic villi Anatomy 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- 201000010918 connective tissue cancer Diseases 0.000 claims description 4
- 210000002249 digestive system Anatomy 0.000 claims description 4
- 201000004101 esophageal cancer Diseases 0.000 claims description 4
- 208000024519 eye neoplasm Diseases 0.000 claims description 4
- 201000010536 head and neck cancer Diseases 0.000 claims description 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 4
- 208000029824 high grade glioma Diseases 0.000 claims description 4
- 206010023841 laryngeal neoplasm Diseases 0.000 claims description 4
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 4
- 201000011614 malignant glioma Diseases 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 4
- 201000008106 ocular cancer Diseases 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 230000000241 respiratory effect Effects 0.000 claims description 4
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 4
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 4
- 201000003120 testicular cancer Diseases 0.000 claims description 4
- 201000002510 thyroid cancer Diseases 0.000 claims description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 4
- 206010046766 uterine cancer Diseases 0.000 claims description 4
- 208000003200 Adenoma Diseases 0.000 claims description 2
- 206010001233 Adenoma benign Diseases 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 2
- 201000000053 blastoma Diseases 0.000 claims description 2
- 208000035269 cancer or benign tumor Diseases 0.000 claims description 2
- 238000002659 cell therapy Methods 0.000 claims description 2
- 201000008184 embryoma Diseases 0.000 claims description 2
- 210000002615 epidermis Anatomy 0.000 claims description 2
- 210000004392 genitalia Anatomy 0.000 claims description 2
- 208000016847 malignant urinary system neoplasm Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 208000037819 metastatic cancer Diseases 0.000 claims description 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims description 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 2
- 238000010361 transduction Methods 0.000 claims description 2
- 230000026683 transduction Effects 0.000 claims description 2
- 210000004881 tumor cell Anatomy 0.000 claims description 2
- 230000002485 urinary effect Effects 0.000 claims description 2
- 201000004435 urinary system cancer Diseases 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims 3
- 238000011467 adoptive cell therapy Methods 0.000 claims 1
- 230000000112 colonic effect Effects 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 230000002601 intratumoral effect Effects 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 3
- 108091008874 T cell receptors Proteins 0.000 description 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 3
- 238000001890 transfection Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 208000026691 scrotum cancer Diseases 0.000 description 1
- 201000001814 scrotum neoplasm Diseases 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762540901P | 2017-08-03 | 2017-08-03 | |
| US62/540,901 | 2017-08-03 | ||
| PCT/US2018/044740 WO2019028098A1 (en) | 2017-08-03 | 2018-08-01 | METHODS AND COMPOSITIONS FOR TREATING CANCER |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020529847A JP2020529847A (ja) | 2020-10-15 |
| JP2020529847A5 true JP2020529847A5 (enExample) | 2021-09-09 |
Family
ID=65234162
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020505464A Pending JP2020529847A (ja) | 2017-08-03 | 2018-08-01 | がんの処置のための方法および組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20200155600A1 (enExample) |
| EP (1) | EP3661953A4 (enExample) |
| JP (1) | JP2020529847A (enExample) |
| KR (1) | KR20200036874A (enExample) |
| CN (1) | CN111094328A (enExample) |
| AU (1) | AU2018308982A1 (enExample) |
| CA (1) | CA3071448A1 (enExample) |
| IL (1) | IL272147A (enExample) |
| SG (1) | SG11202000724XA (enExample) |
| WO (1) | WO2019028098A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020272664A1 (en) * | 2019-04-08 | 2021-11-04 | Taiga Biotechnologies, Inc. | Compositions and methods for the cry opreservation of immune cells |
| AU2020274117A1 (en) * | 2019-05-14 | 2021-12-02 | Taiga Biotechnologies, Inc. | Compositions and methods for treating T cell exhaustion |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6358739B1 (en) * | 1999-04-12 | 2002-03-19 | Modex Therapeutiques, S.A. | Transiently immortalized cells |
| ES2386884T3 (es) * | 2000-11-01 | 2012-09-04 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Vectores de expresión capaces de inducir respuesta inmunomejorada y métodos para usarlos |
| WO2003068941A2 (en) * | 2002-02-13 | 2003-08-21 | Duke University | Modulation of immune response by non-peptide binding stress response polypeptides |
| AU2004316996A1 (en) * | 2003-06-20 | 2005-09-15 | The Regents Of The University Of California | Polypeptide transduction and fusogenic peptides |
| AU2006304392B2 (en) * | 2005-10-18 | 2014-05-01 | National Jewish Health | Conditionally immortalized long-term stem cells and methods of making and using such cells |
| ES2681478T3 (es) * | 2008-08-28 | 2018-09-13 | Taiga Biotechnologies, Inc. | Moduladores de MYC, métodos de uso de los mismos y métodos para identificar agentes que modulan MYC |
| EP2877189B1 (en) * | 2012-07-20 | 2021-01-06 | Taiga Biotechnologies, Inc. | Enhanced reconstitution and autoreconstitution of the hematopoietic compartment |
| US9365825B2 (en) * | 2013-03-11 | 2016-06-14 | Taiga Biotechnologies, Inc. | Expansion of adult stem cells in vitro |
| WO2014170389A1 (en) * | 2013-04-18 | 2014-10-23 | Tilt Biotherapeutics Oy | Enhanced adoptive cell therapy |
| SG11202000612TA (en) * | 2017-08-03 | 2020-02-27 | Taiga Biotechnologies Inc | Methods and compositions for the treatment of melanoma |
| US10149898B2 (en) * | 2017-08-03 | 2018-12-11 | Taiga Biotechnologies, Inc. | Methods and compositions for the treatment of melanoma |
-
2018
- 2018-08-01 CN CN201880057363.5A patent/CN111094328A/zh active Pending
- 2018-08-01 CA CA3071448A patent/CA3071448A1/en active Pending
- 2018-08-01 US US16/635,383 patent/US20200155600A1/en not_active Abandoned
- 2018-08-01 JP JP2020505464A patent/JP2020529847A/ja active Pending
- 2018-08-01 AU AU2018308982A patent/AU2018308982A1/en not_active Abandoned
- 2018-08-01 EP EP18841366.0A patent/EP3661953A4/en not_active Withdrawn
- 2018-08-01 KR KR1020207004465A patent/KR20200036874A/ko not_active Ceased
- 2018-08-01 SG SG11202000724XA patent/SG11202000724XA/en unknown
- 2018-08-01 WO PCT/US2018/044740 patent/WO2019028098A1/en not_active Ceased
-
2020
- 2020-01-20 IL IL272147A patent/IL272147A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sun et al. | Eradication of hepatocellular carcinoma by NKG2D-based CAR-T cells | |
| US20230053849A1 (en) | Anti trbc1 antigen binding domains | |
| JP2021058197A5 (enExample) | ||
| JP2024074801A5 (enExample) | ||
| US11970545B2 (en) | T cell-antigen coupler with Y182T mutation and methods of uses thereof | |
| JP2020517259A5 (enExample) | ||
| TW201619377A (zh) | Ｃａｒ表現載體及ｃａｒ表現ｔ細胞 | |
| JP2019516663A5 (enExample) | ||
| JP2019534246A5 (enExample) | ||
| WO2021147121A1 (zh) | 修饰的免疫细胞及其应用 | |
| JP2018533909A5 (enExample) | ||
| EP4028525A1 (en) | Combined expression of a chimeric cd3 fusion protein and an anti-cd3-based bispecific t cell activating element | |
| IL301995A (en) | Cells comprising t cell-antigen couplers and uses thereof | |
| CN113677707A (zh) | 用于在治疗癌症中增强效力的il-4/il-13途径抑制剂 | |
| JP2020529847A5 (enExample) | ||
| JPWO2020154617A5 (enExample) | ||
| Long et al. | HLA-class II restricted TCR targeting human papillomavirus type 18 E7 induces solid tumor remission in mice | |
| CN115023237A (zh) | 癌症或肿瘤的治疗方法 | |
| Tang et al. | Bispecific antibodies progression in malignant melanoma | |
| WO2022033483A1 (zh) | 多功能的免疫效应细胞及其应用 | |
| CN115850509B (zh) | 抗原结合蛋白及其用途 | |
| US12479903B2 (en) | CD5 specific T cell receptor cell or gene therapy | |
| Feng et al. | Nanobody-Directed CEA-targeting CAR T Cells Eliminate Gastrointestinal Cancer Xenografts | |
| CN108025044B (zh) | 免疫原性降钙素原前体肽 | |
| US20240226210A9 (en) | Oncolytic virus combined with car t cells for anti-tumor therapy |